NRAS and neoplasm: In response to the results of these clinical trials, the ESMO consensus guideline recommends expanding RAS mutational analysis to at least KRAS exons 2, 3, and 4 (codons 12, 13, 59, 61, 117, and 146) and NRAS exons 2, 3, and 4 (codons 12, 13, 59, 61, and 117) alongside the assessment of tumor BRAF mutational status.